Systemic Lupus Erythematosus: key endpoint results by drug
The key endpoints of Systemic Lupus Erythematosus trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Systemic Lupus Erythematosus page.
SRI-4
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 29% | 22.9% | +6.1 | wk 24 · n 31 | NCT02270957 Phase 2, secondary |
| Anifrolumab | 36.1% | 40.2% | −4.1 | 300 mg · wk 52 · n 180 | NCT02446912 Phase 3, primary |
| baricitinib | 47.1% | 45.6% | +1.5 | 4 mg · wk 52 · n 258 | NCT03616964 Phase 3, primary |
| deucravacitinib | 44.9% | 34.4% | +10.5 | 12 mg · wk 32 · n 89 | NCT03252587 Phase 2, primary |
| Litifilimab | 56.3% | 28.6% | +27.7 | 450 mg · wk 24 · n 64 | NCT02847598 Phase 2, secondary |
| rezpegaldesleukin | 27.4% | 29.7% | −2.3 | High dose · wk 24 · n 73 | NCT04433585 Phase 2, secondary |
| upadacitinib | 54.4% | 38.7% | +15.7 | 60 mg/30 mg · wk 24 · n 68 | NCT03978520 Phase 2, secondary |
| ustekinumab | 61.7% | 33.3% | +28.4 | wk 24 · n 60 | NCT02349061 Phase 2, primary |
Drugs checked with no result here: 54 not reported, 2 trial running, 2 not posted.
BICLA
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 25.8% | 22.9% | +2.9 | wk 24 · n 31 | NCT02270957 Phase 2, primary |
| Anifrolumab | 47.8% | 31.3% | +16.5 | 300 mg · wk 52 · n 180 | NCT02446899 Phase 3, primary |
| deucravacitinib | 36% | 25.6% | +10.4 | 12 mg · wk 48 · n 89 | NCT03252587 Phase 2, secondary |
| rezpegaldesleukin | 20% | 30% | −10 | High dose · wk 24 · n 60 | NCT04433585 Phase 2, secondary |
| upadacitinib | 54.4% | 42.7% | +11.7 | 60 mg/30 mg · wk 24 · n 68 | NCT03978520 Phase 2, secondary |
| ustekinumab | 35% | 33.3% | +1.7 | wk 24 · n 60 | NCT02349061 Phase 2, secondary |
Drugs checked with no result here: 55 not reported, 3 trial running, 2 not posted.
CLASI-50
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Anifrolumab | 41.4% | 25.9% | +15.5 | 300 mg · wk 12 · n 58 | NCT02446912 Phase 3, secondary |
| baricitinib | 58% | 66.1% | −8.1 | 4 mg · wk 52 · n 50 | NCT03616964 Phase 3, secondary |
| deucravacitinib | 62.1% | 16.7% | +45.4 | 12 mg · wk 48 · n 29 | NCT03252587 Phase 2, secondary |
| Litifilimab | 37.5% | 12.1% | +25.4 | 450 mg · wk 12 · n 48 | NCT02847598 Phase 2, secondary |
Drugs checked with no result here: 57 not reported, 3 trial running, 2 not posted.
Steroid sparing
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Anifrolumab | 40.8% | 32.4% | +8.4 | 300 mg · wk 52 · n 103 | NCT02446912 Phase 3, secondary |
| baricitinib | 34.3% | 31.7% | +2.6 | 4 mg · wk 52 · n 105 | NCT03616964 Phase 3, secondary |
Drugs checked with no result here: 57 not reported, 5 trial running, 2 not posted.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 66 approved or late-stage drugs with a featured trial in Systemic Lupus Erythematosus were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.